M&A Deal Summary |
|
|---|---|
| Date | 2017-01-04 |
| Target | Perrigo Company - Two ANDA Pharmaceutical Products |
| Sector | Life Science |
| Buyer(s) | Custopharm |
| Sellers(s) | Perrigo Company |
| Deal Type | Divestiture |
SEARCH BY
Custopharm is a generic injectable drug services company. The company specializes in developing a range of generic injectable products, including those with complex formulations. Custopharm also offers regulatory consulting services to help customers with drafting and filing abbreviated new drug applications (ANDAs). Custopharm was formed in 2005 and is based in Carlsbad, California.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: Ireland M&A | 1 of 1 |
| Year: 2017 M&A | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 1887 |
| Sector | Life Science |
| Employees | 8,379 |
| Revenue | 4.4B USD (2024) |
Perrigo Company is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API), as well as receives royalties from Multiple Sclerosis drug Tysabri®. The company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market and an industry leader in pharmaceutical technologies. Perrigo Company was founded in 1887 and is based in Dublin, Ireland.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 9 |
| Sector: Life Science M&A | 1 of 7 |
| Type: Divestiture M&A Deals | 2 of 9 |
| Country: Ireland M&A | 2 of 3 |
| Year: 2017 M&A | 1 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-08-17 |
Geiss Destin & Dunn
Peachtree City, California, United States Geiss, Destin & Dunn, Inc. is a distributor of over-the-counter healthcare and consumer goods products to the non-chain retail and institutional markets. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-02-27 |
TYSABRI
United States TYSABRI (natalizumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS) to slow the worsening of symptoms common in people with MS and to decrease the number of flare-ups (relapses). TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML). When starting and continuing treatment with TYSABRI, it is important to discuss with your doctor whether the expected benefit of TYSABRI is enough to outweigh this risk. |
Sell | $2.9B |
